Everly Health Aquires Women’s Health Brand Natalist

The acquisition brings Natalist's range of fertility and pregnancy essentials into Everly Health's portfolio of women's health offerings

Everly Health the digital health company at the forefront of the virtual diagnostics-driven care industry, today announced its acquisition of Natalist, a women’s health company that offers consumers conception and pregnancy essentials that are thoughtfully designed for ease of use and are 100% plastic neutral. Natalist is the third acquisition by Everly Health this year. Terms of the all-cash transaction were not disclosed.

“Creating innovative solutions for women’s health was my initial motivation for founding Everlywell and remains a top area of focus,” said Julia Cheek, CEO and Founder of Everly Health. “A survey of our customers revealed that nearly 70% don’t trust many of the women’s health products available on the market today.1 Natalist’s thoughtfully designed fertility and pregnancy essentials are the solution that so many women are seeking.”

Since its launch two years ago, Natalist has progressively expanded its product line to support women on their reproductive journeys, both online and in national retailers. The brand’s footprint has grown from 300 to nearly 6,000 brick-and-mortar locations in just the last year.

Both Natalist and Everly Health are led and founded by moms and advised by board-certified physicians. As part of the transaction, Natalist’s full team and executive leadership have joined Everly Health, bringing the company’s portfolio to four subsidiaries: Natalist, Everly Health Solutions, EverlyDx, and Everlywell, the leading brand in at-home collection health and wellness lab testing in the U.S. today.2

“Natalist was created to serve people who are seeking modern, sustainable tools for conception and pregnancy. Everly Health’s full capabilities across testing, telehealth, and virtual care delivery will supercharge our ability to help people in ways we’re only beginning to explore,” stated Vernita Brown, Chief Executive Officer at Natalist. “I’m thrilled to discover what we can accomplish together, as part of Everly Health.”

In addition to its signature pregnancy and ovulation tests, Natalist’s product suite supports women from pre-conception through pregnancy and includes tests, supplements, education, lubricants, and self-care items. Today, Natalist’s most popular products include its Ovulation Tests, Pregnancy Tests, and Prenatal supplements. Natalist’s products expand Everlywell’s existing women’s health offering that includes at-home collection lab tests for menopause, fertility hormones, sexual health, and more. Everlywell was also the first company to launch an at-home collection fertility hormone test to consumers in March 2018.

“Last year, millions of women discovered at-home testing, telehealth, and wellness solutions for the first time — ideal solutions for the busy lives women lead. In fact, Everlywell’s Women’s Health suite of tests has seen a 350% increase in sales this year,” said Jenifer Dasho, Chief Marketing Officer at Everly Health and General Manager of Natalist. “For the millions of women who changed their plans to grow their families due to the pandemic,3 home-based health and wellness solutions are a powerful tool to help gain control over their reproductive journey.”

“The missions of our two companies have been aligned since day one. We’re working to make sure all people — especially women — have access to care that’s simple, convenient, and designed for the way they live,” remarked Halle Tecco, Founder and Chief Women’s Health Officer at Natalist. “Bringing together two brands that are founded and led by women to benefit women everywhere is a great feeling.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”